

Edgar Filing: GAMMACAN INTERNATIONAL INC - Form 8-K

GAMMACAN INTERNATIONAL INC  
Form 8-K  
February 16, 2005

UNITED STATES SECURITIES AND  
EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 13, 2005

GAMMACAN INTERNATIONAL, INC.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of incorporation)

0-32835  
(Commission File Number)

33-0956433  
(IRS Employer Identification No.)

11Ben Gurion St., 54100 Givat Shmuel, Israel  
(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code 972 3 5774475

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On February 13, 2005, each of Gammacan International, Inc. and our subsidiary, Gammacan, Ltd., appointed Dr. Lior Soussan-Gutman as a member of such company's Board of Directors. Dr. Lior Soussan-Gutman, age 40, has managed Teva Pharmaceuticals' Oncotest unit since January 2003. Dr. Soussan-Gutman was the founder and CEO of Oncotest Ltd., a company offering specialized cancer diagnostic services to the oncology community based on a network of laboratories around the world. Dr. Soussan-Gutman founded Oncotest Ltd. in 1998 and acted as CEO from that time until January 2003. Dr. Soussan-Gutman holds a Ph.D. in Neurobiochemistry from the Tel-Aviv University and she did Post-doctorate

Edgar Filing: GAMMACAN INTERNATIONAL INC - Form 8-K

research in molecular biology at the Weizmann Institute of Science. Dr. Soussan-Gutman will not be appointed to any Board committees at this time.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GAMMACAN INTERNATIONAL, INC.

/s/ DAN J. GELVAN

-----  
Dan J. Gelvan,  
Chief Executive Officer

Date: February 16, 2005

3